Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/12/2928329/0/en/4DMT-to-Participate-in-the-H-C-Wainwright-4th-Annual-Ophthalmology-Virtual-Conference.html
https://www.globenewswire.com/news-release/2024/08/08/2927351/0/en/4DMT-Reports-Second-Quarter-2024-Financial-Results-and-Operational-Highlights.html
https://www.globenewswire.com/news-release/2024/08/05/2924217/0/en/4DMT-Advances-Leadership-in-Large-Market-Ophthalmology-with-Senior-Management-Hires-and-Formation-of-Ophthalmology-Advisory-Board.html
https://4dmt.gcs-web.com/news-releases/news-release-details/4dmt-announces-positive-phase-2-prism-interim-results
https://www.globenewswire.com/news-release/2024/07/17/2914359/0/en/4DMT-Announces-Positive-Phase-2-PRISM-Interim-Results-for-Intravitreal-4D-150-in-a-Broad-Wet-AMD-Population-Affirming-Favorable-Safety-Profile-and-Robust-Clinical-Activity.html
https://www.globenewswire.com/news-release/2024/06/18/2900361/0/en/4DMT-to-Present-Initial-Interim-24-week-Landmark-Analysis-from-the-4D-150-Phase-2-PRISM-Population-Extension-Cohort-in-a-Broad-Wet-AMD-Population-at-ASRS-and-Host-a-Corporate-Webca.html
https://www.globenewswire.com/news-release/2024/06/08/2895689/0/en/4DMT-Presents-Injection-Free-Subgroup-Analyses-from-4D-150-Phase-2-PRISM-Randomized-Dose-Expansion-Cohort-in-Wet-AMD-Patients-with-Severe-Disease-Activity-High-Treatment-Burden-at-.html
https://www.globenewswire.com/news-release/2024/06/06/2894575/0/en/4DMT-Presents-Positive-Interim-Data-from-Phase-1-2-AEROW-Clinical-Trial-of-Aerosolized-4D-710-for-Modulator-Ineligible-Intolerant-Cystic-Fibrosis-at-47th-European-Cystic-Fibrosis-C.html
https://www.globenewswire.com/news-release/2024/06/04/2892986/0/en/4DMT-Announces-Presentations-at-Clinical-Trials-at-the-Summit-2024-Meeting.html
https://www.globenewswire.com/news-release/2024/06/03/2892196/0/en/4DMT-to-Participate-in-Upcoming-Investor-Conferences.html